xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

449

Orlandi et al.

(Continues)

ESS is associated with improved asthma control, but not lung

function as measured by FEV1.

Among patients with AERD, AD improves upper and lower airway patient reported outcomes with

decreased corticosteroid utilization and increased peak nasal inspiratory airflow.

TABLE X-3 Evidence for the association of CRSwNP and asthma Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Ramonell 1366 2020 1 Meta-analysis Patients with severe eosinophilic asthma treated with either benralizumab, dupilumab, mepolizumab or reslizumab Frequency of acute asthma exacerbations All mAbs decreased the frequency asthma exacerbations in patients with eosinophilic asthma. Vashishta 1360 2013 1 Systematic review and meta-analysis Studies reporting asthma outcomes among CRS Overall asthma control (symptoms, FEV1,

Dupilumab was well tolerated and reduced NPS, sinus opacification, and severity of sinonasal symptoms.

ESS improved mean asthma symptom scores and peak

expiratory flow as well as all nasal outcomes

No significant difference between fluticasone and placebo cohorts,

potentially due to shared impact of ESS.

medication utilization) Frequency of asthma attacks and hospitalizations

Changes from baseline to 6months in

Peak nasal inspiratory flow

Changes from baseline to week 24 in NPS, congestion and obstruction

Changes from baseline to 21 weeks in: Nasal outcomes

(symptoms, polyp score, peak flow, butanol test)

Lower airway outcomes (symptoms, incentive

spirometry and mean

daily peak expiratory flow)

PROMs (SNOT-22, ACQ) Rescue medication

Inflammatory mediators

Ehnhage 1355 2009 2 RCT CRSwNP and asthma treated with ESS and 400 μ g fluticasone proprionate nasal drops vs placebo

patients undergoing ESS

desensitization and 624 mg daily vs placebo

ATA with nasal polyps under the same protocol

Sinus 24: dupilumab 300 mg every 2 weeks for 24 weeks

Sinus 52: dupilumab 300 mg every 2 weeks for 52 weeks

Swierczyńska Krępa 1367 2014 2 PilotRCT AERD treated with aspirin

Bachert 60 2019 2 Meta-analysis of 2 RCTs